-
1.发明公开COMBINATIONS OF ESZOPICLONE AND O-DESMETHYLVENLAFAXINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS 审中-公开ESZOPICLONE和O-DESMETHYLVENLAFAXINE的联合治疗及治疗偏头痛，情绪低落，焦虑和认知障碍的方法
公开(公告)号：EP1904046A2
公开(公告)日：2008-04-02
申请号：EP06786362.1
申请日：2006-07-05
申请人： Sepracor Inc.
发明人： CARON, Judy , WESSEL, Thomas , LALJI, Karim , VARNEY, Mark, A.
IPC分类号： A61K31/135 , A61K31/495
CPC分类号： A61K31/4985 , A61K31/137 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
摘要翻译： 本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂在一起时可用于治疗例如绝经，心境障碍，焦虑症或认知障碍。 药物组合物的第一组分是镇静性右佐匹克隆。 药物组合物的第二组分是O-去甲基文拉法辛。 本发明还涉及治疗更年期，围绝经期，情绪障碍，焦虑症和认知障碍的方法。
-
2.发明公开
公开(公告)号：EP1898915A2
公开(公告)日：2008-03-19
申请号：EP06786363.9
申请日：2006-07-05
申请人： Sepracor Inc.
发明人： CARON, Judy , WESSEL, Thomas , LALJI, Karim , VARNEY, Mark, A.
IPC分类号： A61K31/495
CPC分类号： A61K31/4985 , A61K31/343 , A61K31/381 , A61K31/4745 , A61K45/06 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
-
3.发明公开COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, AND METHODS OF TREATMENT OF MENOPAUSE AND MOOD, ANXIETY, AND COGNITIVE DISORDERS 有权艾司佐匹克隆和组合的反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式-4-（3,4-二氯苯基）-1,2,4- 3,4-四氢-1-萘胺为绝经，围绝经期和学习障碍于治疗
公开(公告)号：EP1904066A2
公开(公告)日：2008-04-02
申请号：EP06786496.7
申请日：2006-07-06
申请人： Sepracor Inc.
发明人： CARON, Judy , WESSEL, Thomas , LALJI, Karim , VARNEY, Mark , BAKALE, Roger P. , SINGH, Surendra P. , WILKINSON, H. Scott , SU, Xiping , HAN, Zhengxu , KOENIG, Stephan G.
IPC分类号： A61K31/498
CPC分类号： A61K31/4985 , A61K31/135 , C07C211/42 , C07C2602/10 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
摘要翻译： 本发明的一个方面涉及含有两种或多种活性剂的药物组合物做了当一起可用于治疗，E. G.，绝经，心境障碍，焦虑症，或认知障碍。 所述药物组合物的第一组分是镇静剂艾司佐匹克隆。 所述药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基）-1， -1,2,3,4-四氢-1-萘胺。 因此，本发明涉及治疗绝经，围绝经，心境障碍，焦虑症，和认知障碍的方法。
-
公开(公告)号：EP1732559A2
公开(公告)日：2006-12-20
申请号：EP05734186.9
申请日：2005-04-05
申请人： SEPRACOR, INC.
发明人： WESSEL, Thomas , CARON, Judy
IPC分类号： A61K31/4985 , A61P25/04 , A61P29/00 , A61P25/02 , A61P19/02 , A61P25/00 , A61P15/12 , A61P25/28 , A61P9/10 , A61P25/20
CPC分类号： A61K31/4985 , Y02A50/401
摘要： The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.
-
5.发明公开COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION 有权镇静剂组合以及为改进抑郁症的治疗质量和睡眠的神经递质调制器和方法
公开(公告)号：EP1691811A1
公开(公告)日：2006-08-23
申请号：EP04813295.5
申请日：2004-12-08
申请人： SEPRACOR, INC.
IPC分类号： A61K31/4985 , A61K31/138 , A61P25/20 , A61P25/24
CPC分类号： A61K31/4985 , A61K31/137 , A61K31/138 , A61K31/495 , A61K31/724 , A61K45/06 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
-
-
-
-
搜索结果
5 条记录 (耗时 0.02 秒)
